To fully investigate its therapeutic potential in FLT3-ITD+ AML, we assessed TP-0903 in FLT3-ITD+ AML cell lines including MOLM13, MV4-11, and MOLM13-RES. This evidence concerns the gene FLT3 and acute myeloid leukemia.